COLORADO SPRINGS, Colo., July 6, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, sees the payment of millions of dollars in fees to GW Pharmaceuticals by major international pharmaceutical companies as confirmation of the validity of its own strategy and proof that more and more people have found that cannabis provides safe and effective medicines that are greatly needed.
